Olympus-RMS Develops Cultured Chondrocyte Implantation TherapyExpected to Simplify Treatment of Knee Cartilage Defects
November 29, 2018
Olympus-RMS Corporation, a joint venture between Olympus Corporation and SEWON CELLONTECH Corporation of South Korea, announced today that it has developed a Cultured Chondrocyte Implantation (CCI) Kit that is expected to vastly simplify cartilage implants and minimize the burden of treatment on patients. Clinical trials are set to commence in Japan.
Press releases are company announcements that are directed at the news media.
Information posted on this site is current and accurate only at the time of their original publication date, and may now be outdated or inaccurate.